Of the predicted upstream regulators of the DEGs, CREB1, ERB2 and BMP2 were activated, as was the pathway that is modulated by the anti-Type 2 Diabetes pharmaceutical agent Troglitazone (Table 4; Supplementary Table 5). Here, BMP2 is linked to type 2 diabetes mellitus.